Global Biosensors Market to Reach US$ 55.4 Billion by 2032, Stimulated by Increasing Prevalence of Chronic Diseases

According to the latest report by IMARC Group, titled “Biosensors Market Report by Product (Wearable Biosensors, Non-Wearable Biosensors), Technology (Electrochemical Biosensors, Optical Biosensors, Piezoelectric Biosensors, Thermal Biosensors, Nanomechanical Biosensors, and Others), Application (Blood Glucose Testing, Cholesterol Testing, Blood Gas Analysis, Pregnancy Testing, Drug Discovery, Infectious Disease Testing, and Others), End Use (Point of Care Testing, Home Healthcare Diagnostics, Research Laboratories, Security and Biodefense, and Others), and Region 2024-2032” the global biosensors market size reached US$ 28.8 Billion in 2023. Biosensors are analytical devices that combine a biological component with a transducer to detect and convert a biological signal into a quantifiable output. They play a pivotal role in diagnostics, enabling the rapid and accurate detection of various biomarkers. They aid in early detection of diseases, such as cancer and infectious diseases, facilitating timely interventions. They are also instrumental in assessing the quality of air, water, and soil by detecting contaminants and pollutants. Furthermore, they can detect allergens, pathogens, and spoilage indicators, ensuring the production of safe and high-quality food products.

Global Biosensors Market Trends:

At present, the growing demand for biosensors to detect specific biomarkers and pathogens represents one of the key factors offering a favorable market outlook. Biosensors also enable point-of-care (POC) testing, early disease detection, and personalized medicine, making them indispensable in modern healthcare. In addition, biosensors are essential tools for managing and monitoring chronic diseases, such as diabetes and cardiovascular disorders conditions. The ability of biosensors to provide real-time data empowers patients to take proactive measures in managing their health, which is contributing to the growth of the market. Moreover, increasing environmental concerns are leading to a growing need for monitoring and mitigating pollution. This, in turn, is catalyzing the demand for biosensors, as their high sensitivity and specificity make them invaluable in assessing environmental quality. Looking forward, the market value is projected to reach US$ 55.4 Billion by 2032, expanding at a CAGR of 7.3% during 2024-2032.

Market Summary:

• Based on the product, the market has been bifurcated into wearable biosensors and non-wearable biosensors. At present, non-wearable biosensors represent the largest market share.
• On the basis of the technology, the market has been segmented into electrochemical biosensors, optical biosensors, piezoelectric biosensors, thermal biosensors, nanomechanical biosensors, and others. Presently, electrochemical biosensors exhibit a clear dominance in the market.
• Based on the application, the market has been classified into blood glucose testing, cholesterol testing, blood gas analysis, pregnancy testing, drug discovery, infectious disease testing, and others. Blood glucose testing currently dominates the market.
• On the basis of the end use, the market has been segregated into point of care testing, home healthcare diagnostics, research laboratories, security and biodefense, and others. Presently, point of care testing holds the biggest market share.
• Region-wise, the market has been segmented into North America (United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. Amongst these, North America enjoys the leading position in the market.
• The competitive landscape of the market has also been examined, with some of the key players being Abbott Laboratories, AgaMatrix Inc. (WaveForm Technologies Inc), DuPont de Nemours Inc., F. Hoffmann-La Roche AG, General Electric Company, LifeScan Inc. (Platinum Equity LLC), Medtronic PLC, Nova Biomedical Corporation, PHC Holdings Corporation, Siemens AG, and Thermo Fisher Scientific Inc.

Report Scope:

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Group
134 N 4th St.
Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800